トピック

#biotechnology

7 件の記事

#regenxbio #healthcare #conference-presentation #alnylam-pharmaceuticals #brezosiran #huntingtons-disease #rnai-therapy #amgen-inc #medical-oncology #moderna-inc #cancer-immunotherapy #clinical-trials

株式·1 週間前

Immunic, Inc. (IMUX) Presents at 10th Joint ACTRIMS-ECTRIMS Meeting - MSToronto2026 - Slideshow (NASDAQ:IMUX) 2026-10-27

Immunic, Inc. presented at the 10th Joint ACTRIMS-ECTRIMS Meeting, sharing key updates via a slideshow. This presentation likely focused on the company's advancements in its research and development pipeline, particularly concerning its work in treating inflammatory diseases.

639635712

株式·1 週間前

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Alnylam Pharmaceuticals held an RNAi roundtable discussing exon 1 targeting with Brezosiran for Huntington's Disease. This event highlights ongoing research and development in treating neurodegenerative diseases using RNA interference technology.

645913511

株式·2 週間前

Amgen Inc. (AMGN)が2026年ヨーロッパ医療オンコロジー会議（ESMO）年次総会のトランスクリプトを発表

Amgen Inc.は2026年ヨーロッパ医療オンコロジー年次総会で、企業の最新の開発について議論した。このイベントは、企業の医療オンコロジーの進歩を示すものとして重要である。プレゼンテーションは、Amgen Inc.に対する投資家の意見を影響させる可能性がある。

AMGN

553139112

株式·2 週間前

Moderna, Inc. (MRNA)がIntismeranのPhase IIIデータとがん免疫療法の進歩について議論するトランスクリプト

Moderna, Inc.はIntismeranのPhase IIIデータとがん免疫療法の進歩について議論し、医療研究の進歩を示した。この開発は、がん治療の進歩を示す企業の取り組みを示すものとして重要である。Moderna, Inc.の議論は、企業に対する投資家の意見を影響させる可能性がある。

MRNA

920525012

株式·2 週間前

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

REGENXBIO Inc. provided an update on its clinical programs for Wet Age-related Macular Degeneration (AMD) and rare diseases. The company also discussed its commercial outlook.

1696366

株式·2 週間前

REGENXBIO Inc. To Host Investor Event Transcript

REGENXBIO Inc. hosted an investor event on October 20, 2026, to discuss company updates. A transcript of the event, edited for accuracy, has been made available.

520329512

株式·3 週間前

PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17

PDS Biotechnology Corporation has discussed its PDS-0301 immunocytokine and its role in treating metastatic colorectal cancer. The company has presented a slideshow highlighting the potential of this treatment. This development may impact the biotechnology sector and the treatment of colorectal cancer.

NASDAQ:PDSB

141966193